Life Sciences Tools and Services
Company Overview of Avelas BioSciences, Inc.
Avelas BioSciences, Inc. develops molecularly-targeted in vivo imaging technologies. It offers Avelas Cancer Illuminator, a fluorescent peptide that uses elevated protease activity of invading and metastasizing cancer to fluorescently label cancerous tissue with high sensitivity and specificity; and creates an illuminated cancer map for the surgeon during the operation when used with a fluorescence imaging system. The company also provides Avelas Nerve Illuminator, a fluorescent peptide that selectively illuminates peripheral nerves. Avelas BioSciences, Inc. was incorporated in 2008 and is based in La Jolla, California.
11099 North Torrey Pines Road
La Jolla, CA 92037
Founded in 2008
Key Executives for Avelas BioSciences, Inc.
Chief Executive Officer, President and Director
Co-Founder and Research Collaborator
Vice President of Clinical Affairs
Compensation as of Fiscal Year 2015.
Avelas BioSciences, Inc. Key Developments
Avelas Biosciences Initiates Clinical Trial Enrollment for Cancer Illuminator to Increase Surgical Accuracy for Breast Cancer Starts At Ucsf
Oct 29 15
Avelas Biosciences announced that clinical trial enrollment has initiated at the University of California, San Francisco (UCSF) for the company's in vivo surgical diagnostic agent, AVB-620, for breast cancer. AVB-620 is a fluorescent, cancer-illuminating probe that is designed to enable cancer surgeons to distinguish tumor tissue from normal during surgery, potentially preventing the need for many secondary surgeries to ensure complete tumor removal. The open-label dose escalation study will enroll up to 39 women with stage I-III breast cancer and will evaluate AVB-620 safety and pharmacokinetics, as well as determine the dose needed to generate fluorescence signals in tumor and lymph node tissues sufficient for visualization and image analysis. The study is also enrolling patients at Moores Cancer Center at UC San Diego Health.
Avelas BioSciences, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 03:30 PM
Sep 3 15
Avelas BioSciences, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 03:30 PM. Venue: Parc 55 Hotel, San Francisco, California, United States.
Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients
Apr 16 15
Avelas Biosciences announced that it has initiated a Phase 1b study of its lead fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent breast cancer undergoing surgery. The open label, dose escalation study will enroll up to 39 women with stage I-III breast cancer undergoing lumpectomy or mastectomy and lymph node assessment. The study will evaluate AVB-620 safety and tolerability, pharmacokinetics, and determine the dose needed to generate fluorescence signals in tumor and lymph node tissues to enable recordings and image analysis. Additionally, the study will evaluate the effect of timing of AVB-620 administration, relative to surgery, on fluorescence characteristics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|